What is Mismatch negativity?
We've applied our expertise in EEG to develop rodent mismatch negativity (MMN) - regarded as one of the most highly-translatable biomarkers for schizophrenia. MMN is a human scalp recorded event related potential (ERP) component evoked by a sound which deviates from a repeating pattern of recent sounds. MMN is generated by a temporo-frontal network including the auditory cortex and is known to be diminished in schizophrenic patients. This disruption can be mimicked by NMDA antagonists (e.g. ketamine) treatment in healthy volunteers. Via collaborations with Cadent and Lundbeck, we have thoroughly validated our MMN protocols with NMDA antagonists such as MK-801, PCP and ketamine in rodents using in-vivo EEG, demonstrating the utility of MMN as a potential translational marker for novel treatments for schizophrenia.
Whether you are interested in Mismatch Negativity, pain models, sleep models or anything in between, please don’t hesitate to contact us. We are committed to offering on-time data delivery and offering flexibility in dealing with and structuring your project. To achieve this we will work alongside you in collaborative research, via contract work or in a full-time capacity - wherever you are around the globe.
Our elegant electrophysiological approach enables detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compounds, benchmarked against NMDA antagonists, (ketamine, MK-801, PCP). Furthermore, our battery of rodent cognition tests provides the opportunity for assessing whether NCEs have the potential utility for treating a range of cognitive impairments associated with schizophrenia compared to atypical antipsychotics such as clozapine.
This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here or to get your project underway please do contact us.